Remepy is pioneering hybrid drugs, and redefining combination therapy. Our mission is to bring better personalized care to patients.


Or Shoval


Dr. Michal Tsur


Prof. Amir Amedi

Chief Scientific Officer

Dr. Nira Saporta

Chief Therapeutics Officer

Shahar Shelly, MD

Chief Medical Officer

Sheila Oren, MD

Chief Parkinson Program

Jonathan Amit-Kanarek


Dr. Ofer Tur-Sinai

General Counsel

Dr. Shai Elrich

Chief Clinical Operations Officer

Lior Benderski

VP Product

Dr. Merav Catalogna

Director of Neuroscience

Dr. Bar Nathansohn-Levi

Director of Immunology

Board and Advisors

Danny Bar Zohar, MD

Board Member

Global Head of Research & Development and Chief Medical Officer at Merck.

Prof. Michal Schwartz

Scientific Advisor

Professor of Neuroimmunology at the Weizmann Institute of Science, responsible for discovery of the key role of the immune system in brain function and repair.

Jessica J. Federer

Industry Advisor

Digital health expert, investor, and board member. Formerly the Chief Digital Officer at Bayer and currently board member at Sage Therapeutics (SAGERX).

Jonathan MacQuitty

Industry Advisor

Serial life science and healthcare entrepreneur, executive and venture capitalist.

Interested in joining us in developing the future hybrid drugs?

Join us

June 6, 2024

Israeli Startup Combines Software With Medicine To Transform $1.6 Trillion Pharma Market

May 1, 2024

Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market

February 14, 2024

Naftali Bennett joins board of Israeli biotech co

September 1, 2023

Health Innovators – Or Shoval and Shahar Shelly

February 5, 2024

Brain chips will give us super abilities in the future

March 3, 2023

New sound navigation technology enables the blind to navigate

March 5, 2023

New technology enables the blind to navigate - Israeli study